title: Kinase profiling in early stage drug discovery: sorting things out.
abstract: Protein kinases represent one of the largest superfamilies of drugable targets and a major research area for both the pharmaceutical industry and academic groups. This has resulted in the emergence of numerous screening technologies and services dedicated to kinase profiling. In spite of this plentiful offering, the field is not without its own pitfalls, as the profusion of reported conditions and data can ultimately complicate interpretation of project results. Here, we discuss how kinase profiling was used in our early stage drug discovery efforts, from the perspective of a smaller biotech relying largely on assay outsourcing.
authors.affiliation: Amakem Therapeutics N.V. Agoralaan Abis, 3590 Diepenbeek, Belgium. Electronic address: olivier.defert@amakem.com.
authors.forename: Olivier
authors.initials: O
authors.lastname: Defert
authors.affiliation: Amakem Therapeutics N.V. Agoralaan Abis, 3590 Diepenbeek, Belgium.
authors.forename: Sandro
authors.initials: S
authors.lastname: Boland
mesh_terms: D000818:Animals; D001665:Binding Sites; D001681:Biological Assay; D055808:Drug Discovery / Q000379:methods*; D006801:Humans; D015394:Molecular Structure; D047428:Protein Kinase Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D011494:Protein Kinases / Q000235:genetics / Q000378:metabolism*; D013329:Structure-Activity Relationship
chemical_list: D047428:Protein Kinase Inhibitors; D011494:Protein Kinases